These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 15337646)
1. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Yoshida K; Takahashi H; Higuchi H; Kamata M; Ito K; Sato K; Naito S; Shimizu T; Itoh K; Inoue K; Suzuki T; Nemeroff CB Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646 [TBL] [Abstract][Full Text] [Related]
2. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods]. Higuchi H Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280 [TBL] [Abstract][Full Text] [Related]
3. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Yoshida K; Higuchi H; Takahashi H; Kamata M; Sato K; Inoue K; Suzuki T; Itoh K; Ozaki N Hum Psychopharmacol; 2008 Mar; 23(2):121-8. PubMed ID: 18023073 [TBL] [Abstract][Full Text] [Related]
4. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Min W; Li T; Ma X; Li Z; Yu T; Gao D; Zhang B; Yun Y; Sun X Psychopharmacology (Berl); 2009 Aug; 205(3):409-17. PubMed ID: 19468717 [TBL] [Abstract][Full Text] [Related]
5. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970 [TBL] [Abstract][Full Text] [Related]
6. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476 [TBL] [Abstract][Full Text] [Related]
7. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929 [TBL] [Abstract][Full Text] [Related]
8. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646 [TBL] [Abstract][Full Text] [Related]
9. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Puech A; Montgomery SA; Prost JF; Solles A; Briley M Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045 [TBL] [Abstract][Full Text] [Related]
10. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806 [TBL] [Abstract][Full Text] [Related]
11. Serotonin transporter gene polymorphism and antidepressant response. Kim DK; Lim SW; Lee S; Sohn SE; Kim S; Hahn CG; Carroll BJ Neuroreport; 2000 Jan; 11(1):215-9. PubMed ID: 10683861 [TBL] [Abstract][Full Text] [Related]
12. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression. Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426 [TBL] [Abstract][Full Text] [Related]
13. Remarkable effect of milnacipran in the treatment of Japanese major depressive patients. Higuchi H; Yoshida K; Takahashi H; Naito S; Tsukamoto K; Kamata M; Ito K; Sato K; Shimizu T Hum Psychopharmacol; 2002 Jun; 17(4):195-6. PubMed ID: 12404688 [No Abstract] [Full Text] [Related]
14. Milnacipran and selective serotonin reuptake inhibitors in major depression. Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126 [TBL] [Abstract][Full Text] [Related]
15. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Leo RJ; Brooks VL Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117 [TBL] [Abstract][Full Text] [Related]
16. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S; Pletan Y; Solles A; Tournoux A Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Gilmor ML; Owens MJ; Nemeroff CB Am J Psychiatry; 2002 Oct; 159(10):1702-10. PubMed ID: 12359676 [TBL] [Abstract][Full Text] [Related]
18. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Pollock BG; Ferrell RE; Mulsant BH; Mazumdar S; Miller M; Sweet RA; Davis S; Kirshner MA; Houck PR; Stack JA; Reynolds CF; Kupfer DJ Neuropsychopharmacology; 2000 Nov; 23(5):587-90. PubMed ID: 11027924 [TBL] [Abstract][Full Text] [Related]
20. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study. Takano A; Halldin C; Farde L Psychopharmacology (Berl); 2013 Mar; 226(1):147-53. PubMed ID: 23090625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]